Vivus’ Qsymia Sales Still Slim, Even As Costs Bulge
This article was originally published in The Pink Sheet Daily
Executive Summary
The obesity drug maker is pulling out all the stops to make its drug more accessible to patients, but several roadblocks still stand in the way of the drug banking meaningful sales revenue. Meanwhile, the launch and a post-marketing trial of Qsymia are adding up in terms of cost.
You may also be interested in...
Vivus Qsymia Launch Includes Strategy To Overcome Medicare Hurdles
Company reports several hundred prescribers have completed online training as part of the Risk Evaluation and Mitigation Strategy for the weight loss drug, which is moving toward a fourth-quarter entry into the marketplace.
REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.